PHE TB Symposium, 19 Oct 2016
Overcoming scientific and commercial barriers to conquering TB
Convened by Professors Nigel Silman and Seshadri Vasan, Public Health England (PHE)
3 CPD credits approved by the Royal College of Pathologists
Supported by BIA, OBN, One Nucleus and TB Alert
Vandervell Lecture Theatre, The Royal College of Surgeons, 35 - 43 Lincoln's Inn Fields, London, WC2A 3PE
Strategically timed on the afternoon prior to the UK Bioscience Forum
Tuberculosis is an infectious disease that, despite all progress, claims a number of deaths paralleled only by those from HIV/AIDS. In 2015, TB infected 10.5 million people (0.5 million of them multi-drug resistant) and killed 1.4 million people (0.4 million of them HIV+). To achieve an incidence of 100 or fewer cases per million by 2035, we have to overcome both scientific and commercial challenges in diagnostics as well as prevention and treatment. These topics will be covered by this symposium organised by Public Health England (PHE), an operationally autonomous Executive Agency of the UK Department of Health which has TB as one of its seven priorities for the period 2015-2020.
11:30 to 12:25: Arrive at the Edward Lumley Hall for registration and networking. Please finish lunch before arriving or bring a sandwich.
12:30 to 12:35: Welcome and introduction (Dr David Rhodes, Head of Business Development, PHE)
12:35 to 13:00: Setting the scene: TB in England (Dr Sarah Anderson, Head of National TB Office, PHE)
This keynote will briefly summarise the recent epidemiology of TB in England, providing an update on trends and burden of TB at a national and sub-national level to the end of 2015; it will outline how England is working to achieve a year-on-year reduction in TB incidence and a reduction in health inequalities by implementing the Collaborative TB Strategy for England 2015-2020, and in so doing highlight recent developments such as the national roll-out of systematic latent TB infection testing and a toolkit to tackle the needs of under-served populations.
13:00 to 14:15: How do we know it is TB? How can we prevent and treat TB better?
This session will focus on the key scientific challenges pertaining to TB diagnostics, vaccines and drugs and case studies on how PHE scientists are trying to address them in partnership with academia and industry. There will be three talks, each for 20 minutes, followed by panel discussion and Q/A.
Chair: Professor Nigel Silman (Senior Business Development Manager, PHE)
- Diagnostics – Dr Karen Kempsell (Senior Project Team Leader – Diagnostic Technologies, PHE)
- Vaccines – Dr Ann Rawkins (Scientific Leader – TB, PHE)
- Drugs – Dr Joanna Bacon (Senior Project Team Leader – TB Research Programme, PHE)
14:15 to 15:00: Networking and tea break at the Edward Lumley Hall
15:00 to 15:55: What are the commercial barriers to conquering TB?
In this panel discussion, experts from academic, charitable and private sectors will discuss the key commercial challenges pertaining to TB diagnostics, vaccines and drugs, and what can be done to overcome these. There will be short presentations lasting 40 minutes, followed by Q/A.
Chair: Professor Seshadri Vasan (Senior Business Development Manager, PHE)
- Steve Bradley (TB patient advocate & advisor to the CQC)
- Mike Mandelbaum (CEO, TB Alert)
- Dr Rupert Osborn (CEO, IP Pragmatics Limited)
- Gwent Paylor (Business Development Manager, CompanDx Limited)
- Dr Philip Turner (Industry Liaison Lead – NIHR Oxford Diagnostic Evidence Cooperative)
15:55 to 16:50: Strategic priorities for TB leading to 2020
In this session, we will have four opinion leaders outline their TB strategic priorities over the next few years – within the National Infection Service (Professor Crook); as a corporate priority for Public Health England (Professor Heymann); as a Global Health challenge (Professor Abubakar); and from a big pharmaceutical company’s clinical development perspective (Dr Koh).
Chair: Dr David Rhodes (Head of Business Development, PHE)
- Professor Derrick Crook (National Infection Service Director – PHE and Professor of Microbiology – University of Oxford)
- Professor David Heymann CBE (Chairman – PHE Board, Head – Chatham House Centre on Global Health Security and Professor of Infectious Disease Epidemiology – LSHTM)
- Professor Ibrahim Abubakar (Professor of Infectious Disease Epidemiology – UCL and Director – UCL Institute for Global Health)
- Dr Gavin Koh (Director of Clinical Development, GSK)
16:50 to 17:00: Summary, vote of thanks and close (Professor Nigel Silman)
Media enquiries should be directed to PHE’s Senior Communications Manager Clare Cook ( or 02083276732).